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and optimise the reporting of such evaluations. To our knowledge, there are no such 
published guidelines in Spain. Methods: This guidance was designed with the 
main aim of providing authors with recommendations, in the form of a checklist, to 
optimise design and reporting of EE and BIA to be submitted to the Catalan Health 
System (CatSalut) within its harmonization program for pharmaceutical innova-
tion. Results: For a given evaluation, two separate guidelines with corresponding 
checklists assess its methodology, quality, and reporting based on several dimen-
sions. ConClusions: The steps outlined in this first guidance in Spain, although 
not compulsory, will provide useful practical tips for how to go about designing and 
reporting of an EE or a BIA for pharmaceuticals in Catalonia (Spain).
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objeCtives: In recent years, spending on prescription drugs contributes substan-
tially to the continuous growth in health expenditure which is influenced by both 
a rise in the use of existing drugs and by the adoption of new and expensive drugs. 
However, their effectiveness outside of clinical trial settings is often uncertain at the 
time they gain market approval. This uncertainty may reflect a lack of real-world 
outcomes data, as opposed to clinical trials data, for a typical patient population. 
A risk-sharing agreement is a contract between a drug manufacturer and a health 
care provider/payer to help manage uncertainties regarding the cost and effective-
ness of those drugs and serves the interests of both. Guidelines can be very use-
ful to identify these uncertainties and select the pharmaceuticals which are most 
eligible for such an agreement to be implemented. To our knowledge, there are no 
such published guidelines in Spain. Methods: This guidance was designed with 
the main aim of identifying uncertainties, helping select the pharmaceuticals most 
eligible, and defining best type of risk sharing agreement (RSA) / pay per Results 
scheme (PRS) to be implemented between the Catalan Heath System (CatSalut) 
and health care providers/pharmaceutical companies in Catalonia. Results: For 
a given pharmaceutical, two questionnaires identify and score following four vari-
ables related to main uncertainties involved: (1) efficacy/effectiveness uncertainty; 
(2) budget uncertainty; (3) budget impact; and (4) incremental cost-effectiveness 
ratio (ICER) and willingness to pay. Final score guides the best type of agreement 
to be implemented accordingly. ConClusions: The steps outlined in this first 
guidance in Spain, although not compulsory, will provide useful practical tips for 
how to go about setting up an RSA or PRS in Catalonia (Spain). This guide is not a 
substitute for suitable regulatory or legal advice.
HealtH care use & Policy studies – Quality of care
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objeCtives: Patient-centered care (PCC) is a critical component of health care 
management of elderly with multimorbidity, especially for those with co-exist-
ing chronic physical conditions with mental illnesses. However, little is known 
about the association between type of multimorbidity and PCC. The objective of 
this study was to analyze the association between type of multimorbidity and 
PCC. Methods: A retrospective cross-sectional study design was used. Data were 
derived from 2011 Access to Care module of the Medicare Current Beneficiary 
Survey (MCBS). The study sample (N = 10,158) consisted of community-dwelling 
elderly Medicare beneficiaries aged 65 years or older with at least one physical 
chronic condition. Types of multimorbidity (MM) defined as: 1) single physical 
condition (No MM); 2) two or more physical conditions without mental illnesses 
(MM-PI); and 3) both mental and physical conditions (MM-MI&PI). PCC was defined 
using patient-physician communication and patients’ confidence in physician. 
Chi-square tests and logistic regressions were used to test the unadjusted and 
adjusted associations. Results: A lower percentage of elderly Medicare benefi-
ciaries with MM-MI&PI had optimal patient-physician communication (73.5%) 
and high confidence in their physicians (86.1%) as compared to those with No MM 
(79.1% and 90.2%). Without adjustments for health status, elderly with MM-MI&PI 
were less likely to have optimal patient-physician communication (OR = 0.74, 95% 
CI [0.61, 0.88]) and confidence in their physicians (OR = 0.67, 95% CI [0.53, 0.86]) as 
compared to elderly with no MM. The relationship between multimorbidity and 
PCC was not statistically significant after adjusting for general health and func-
tional status. However, those with MM-MI&PI were as likely as those with MM-PI 
to have optimal patient-physician communication and confidence in their physi-
cians. ConClusions: Those with multiple conditions faced poor communication 
and low confidence in doctor as compared to those with single physical condition. 
However, type of multimorbidity was not associated with PCC.
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objeCtives: A BCMA system was introduced to the hospital in June 2012. The pur-
pose of this study is to evaluate the impact of the BCMA system on reducing medi-
cation errors and nurse and pharmacist satisfaction with the system. Methods: 
The nurse satisfaction questionnaire and the pharmacist satisfaction question-
naire for the overall system were designed by 8 experts using content validity 
index (CVI). Medication error rates before and after the implementation of the 
allergic rhinitis, cow’s milk allergy, eczema and obesity). Results: Of 100 stud-
ied children 64% were breastfed (BF), while 36% had artificial nutrition (AN), xBF≤  
6months = 48%, xBF> 6months= 52%. Gastroenteritis: xBF = 1,42 diseases/child/life (D/CH/L), 
xAN = 1,64 D/CH/L, xBF≤  6months = 1,84 D/CH/L, xBF> 6months= 1,23D/CH/L. laryngitis: 
xBF= 0,27D/CH/L, xAN = 0,64 D/CH/L, xBF≤  6months = 0,74D/CH/L, xBF> 6months= 0,20D/
CH/L. bronchitis: xBF= 3,73D/CH/L, xAN= 4,86 D/CH/L, xBF≤  6months = 3,89D/CH/L, 
xBF> 6months= 3,34D/CH/L. Pneumonia: xBF= 0,11D/CH/L, xAN = 0,31 D/CH/L, xBF≤  
6months = 0,26D/CH/L, xBF> 6months= 0,03D/CH/L. allergic rhinitis: xBF= 0,16D/CH/L, xAN 
= 0,28 D/CH/L, xBF≤  6months = 0,21D/CH/L, xBF> 6months= 0,11D/CH/L. cow’s milk allergy: 
xBF= 0,11D/CH/L, xAN = 0,17 D/CH/L, xBF≤  6months = 0,16D/CH/L, xBF> 6months= 0,03D/
CH/L. eczema: xBF= 0,09D/CH/L, xAN = 0,42 D/CH/L, xBF≤  6months = 0,21D/CH/L, 
xBF> 6months= 0,03D/CH/L. obesity: xBF= 0,03D/CH/L, xAN = 0,17 D/CH/L, xBF≤  6months 
= 0,05D/CH/L, xBF> 6months= 0,00D/CH/L. ConClusions: Results of the analysis indi-
cated that breastfed children showed less frequent incidence of all of the studied 
diseases compared to children who had artificial nutrition. Breastfeeding and even 
more importantly the duration of breastfeeding has important positive impact on 
child’s health, lower the occurrence of the diseases, frequency of medication use 
and overall total expenditure on health care.
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objeCtives: Objective was to quantify the specialists’ prescription pattern in Iran 
and to point out the prescribing behavioral differences among several special-
ties. Methods: A retrospective cross-sectional study was carried out on the claim 
data. National prescription data were obtained on the basis of the claims that the 
pharmacies submitted to the insurers during 1 year period of the study. More than 
85 million prescriptions were analyzed using “Rx-Analyst” software that is designed 
and applied by National Committee of Rational Use of Medicines in Iran. Specified 
medical specialties were considered and the World Health Organization prescrip-
tion indicators were used to evaluate the physicians’ prescribing behavior. Results: 
Average items per prescription were ranged from 3.68 in cardiologists’ to 2.06 in 
dermatologists’ prescriptions. The highest and the lowest mean price were belonged 
to neurologists’ and ophthalmologists’ prescriptions, respectively. In addition, 45% of 
patients received antibiotics, 41% of patients received injectable form of drugs, and 
23% received corticosteroids. A high tendency toward prescribing corticosteroids and 
antibiotic as well as an injectable form of medicines was observed among general 
physicians. ConClusions: There is an inevitable need to improve prescription hab-
its among different specialties, especially among general practitioners. This causes 
the policymakers to put more emphasis on priorities such as continuous education.
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objeCtives: Monitoring and measuring prescribing patterns can provide valuable 
information regarding the use of medicines and the overall prescribing behavior. 
In Greece, until recently there was no organized system to monitor and record 
prescribing patterns. The aim of this study is to describe prescribing patterns of 
GPs in primary health care. Methods: A prospective cross-sectional study was 
conducted (March–June 2011). Two geographical areas (rural and semirural) in Crete 
and one urban in Athens were randomly selected and all GPs working in these 
areas in public or private practices were invited to participate. Each GP answered a 
structured questionnaire regarding his/her prescribing patterns and collect data on 
100 patients within a specified period. Prescribed drugs and diagnoses were then 
classified according to the ATC classification system and the ICPC-2 classification 
system respectively. Results: 13 GPs (7 from Crete) participated in the study giving 
data for 1202 patients. 84.5% of the patients received a prescription and the mean 
items prescribed were 2.72. At the 12.4% of the total encounters the patient was 
not present while at 9.9% of all encounters the reason was to ask a prescription 
for medicines already bought from the pharmacy. GPs prescribed at the 96.7% and 
97.5% of these cases respectively. Diseases of the circulatory (24.9%), endocrine 
(23.5%) and musculoskeletal (10.4%) systems were the most commonly recorded 
diagnoses. Overall, 62% of all prescribed medicines were from the cardiovascular 
system, alimentary tract and metabolism and nervous system. 4.8% were antibiotics, 
2.7% were injections, 19.9% were launched in the Greek market after 2001, 4% were 
OTCs, 3.7% were narcotics, 10.8% were generics. ConClusions: This preliminary 
descriptive analysis gives an overview of the prescribing patterns of GPs and high-
lights the areas that pharmaceutical policies should be focused. Further analysis is 
needed to identify the factors that determine this behavior.
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objeCtives: Health economic evaluations (EE) and budget impact analysis (BIA) for 
pharmaceuticals are increasingly being used for decision making. Guidelines can be 
very useful to help authors with the use of proper methodology, assess the quality 
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objeCtives: The economical crisis and the requirements for structural changes 
in all aspects of public health brought a new era of reforms in the country as well 
as the health care system itself. The Pharmaceutical Legislation, both European 
and national, were implemented to protect public and state interests. Application 
of new legislation influenced provider of health care services in different areas. 
Therefore it is important to evaluate the impact and performance on costs and 
revenues of health care services provider. Methods: Monitoring, calculation and 
assessment of costs and revenues with the help of financial analysis indicators 
for years 2003-2012, using financial statements was conducted, with respect to 
profitability, debt, liquidity, working capital and efficiency ratios. These ratios con-
stituted significant information of implementing new health care legislation and 
price policies. Results: In case of profitability, parameter gross profit ranged from 
x2003–2011= 16.1–22.8% (xaverage= 19.2%, Xmean= 19.8%, σ = 2.4), but in 2012 decreased on 
14.3%. Net profit ranged x2003–2011= 12.8–18.3% (xaverage= 14.6%, Xmean= 16.6%, σ = 4.9%), 
while in 2012 reached only 2.3%. Debt parameters varied from x2003–2012= 2.33-4.8 
(xaverage= 3.44, Xmean= 3.06, σ = 0.82), liquidity parameters current ratio x2003–2012= 1.1-
1.7 (Xaverage= 1.43, Xmean= 1.45, σ = 0.15) and quick ratio x2003–2012= 0.7-1.3 (xaver-
age= 1.16, xmean= 1.09, σ = 0.15), working capital ratio x2003–2012= 2,7-12,9, (Xaverage= 9.6, 
Xmean= 10.1, σ = 3.1) and efficiency ratios were measured either. ConClusions: 
Implementation of new health care legislation and price policy that were intended 
to apply restrictive measures to increase system efficiency and cost savings had a 
significant impact on health care services providers by worsening profitability and 
liquidity parameters as key indicators of provider stability. Despite the improvement 
in debt ratio, working capital ratio and efficiency ratios, stability may be threatened 
and may affect the amount of health care services providers.
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objeCtives: This study aims to assess the extent of the restriction on access to 
medicines in Bosnia and Herzegovina in relation to the country’s decentralised 
provision of health care, with three separate state entities and 10 cantons within 
the federation of Bosnia and Herzegovina all having a role in the provision of pub-
lic health care. Methods: A comparison was made between the contents of the 
federal essential drug list and the drug lists of the various entities and cantons, in 
order to ascertain which medicines were available, at what price, and with what 
level of reimbursement. Results: The federal essential list contains the basic INNs 
which must be provided by each canton, but there were some important differences 
between the lists of the various entities and cantons. For example, the range of 
patented and originator medicines available in the Republic of Srpska was greater 
than in the cantons of the federation of Bosnia and Herzegovina in general. Also, 
within the federation, there was some variation in the price of medicines between 
cantons, and an even greater variation between the reimbursement levels paid for 
them. For example, in the Tuzla canton, a package of generic losartan produced by 
Krka was priced at 9.30 convertible marks and reimbursed at 20% by the canton’s 
health insurance fund, while the same package at the same price was reimbursed 
50% in the West Herzegovina canton. ConClusions: The lack of centralised control 
over drug funding means that citizens face variability in access to medicines across 
the spectrum, depending on which entity or canton they live in. Recent regulatory 
changes aimed at bringing greater control into drug pricing have so far failed to 
have any notable impact.
HealtH care use & Policy studies – risk sharing/Performance-based  
agreements
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objeCtives: To compare the Risk-Sharing Schemes (RSSs) proposed in reimburse-
ment applications received by Agency for Health Technology Assessment in Poland 
(AHTAPol) in 2012 and 2013. Methods: Comparative analysis of RSSs proposed in 
reimbursement applications received by AHTAPol in 2012 and 2013 was conducted. 
RSSs were quantitatively and qualitatively analyzed and classified on the basis of 
both Carlson’s approach and the Polish Act on the reimbursement of medicinal 
products. Results: In years 2012 and 2013, 56 reimbursement applications with 26 
proposed RSSs and 80 reimbursement applications with 52 RSSs proposed received by 
AHTAPol, respectively. They were classified into 5 categories according to the Act on 
the reimbursement. The most common category in 2012 was making the official sales 
price dependent on the applicant providing supplies at a reduced price (34.62%). On 
the other hand, in 2013 the most common category was making the official sales price 
dependent on a pay-back of a part of the reimbursement obtained to the entity which 
is obliged to finance benefits with public funds (48.08%). Further categories were also 
analyzed. Among all RSSs proposed in each year, only 17 of 52 in 2013 and 9 of 26 
(1 proposition included more than one category) in 2012 could be classified according 
to the Carlson’s approach. As a Results, most common categories were Price Volume 
Agreements (4 in 2012 and 10 in 2013) and Manufacturer funded treatment initiation 
(4 in 2012 and 6 in 2013). Both in 2012 and 2013, there were only one RSSs dependent 
on the health effects achieved. ConClusions: Most of the propositions both in 2012 
and 2013 are not considered to be RSS according to the Carlson’s approach. In 2013 
compared to 2012 there were less price reduction schemes and more pay-back based 
schemes. There is a strong need for further research.
BCMA system was compared. We also collected the numbers of phone calls for 
tracking stat drugs from Oct 2nd to Nov 15th in 2012. Results: After the implemen-
tation of the BCMA system, the medication error rate was significantly reduced 
from 0.18% to 0.12% (p < 0.05). Pharmacists agreed that the BCMA system pro-
vides assistance in tracking prescriptions (90%), identifying medications (60%), 
and reducing medication errors (53%). However, pharmacists also think that the 
system has increased their routine workload (57%). Nurses agreed that the BCMA 
system can improve patient identification (73%), administration of right medica-
tion (57%), medication administration time (47%), and access to correct prescrip-
tion/medication information (42%). Both pharmacists and nurses were dissatisfied 
with the stability of the system (53%, 69%) and poor barcode sensitivity (47%, 
64%). From Oct 2nd to Nov 15th in 2012, we received 469 phone calls. The average 
of tracing call for drugs is 1.67 times every hour. ConClusions: BCMA system 
significantly decreases medication error rate in the hospital. It is recognized to be 
able to improve medication safety by both pharmacists and nurses. Improving the 
quality of associated computer equipment is the next important step.
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objeCtives: Our study evaluates the preferred methods which the pharmaco-
economic evaluations submitted for reimbursement purposes in Bulgaria are 
using. Methods: This is retrospective, descriptive study. We have examined 
all applications submitted to National Council on Pricing and Reimbursement 
in 2013 on which positive opinion was issued. Quantitatively and qualitatively 
descriptive analyses towards the new molecules were carried out based on 
the submitted pharmacoeconomic evaluations. Results: 22 new INNs were 
submitted and approved for reimbursement during the studied period (average time 
for approval: 194.55 days). Only 18.18% (n= 4) were orphan drugs. The most com-
monly used types of pharmacoeconomic evaluation were cost-effectiveness analysis 
(n= 10), followed by cost-minimization analysis (n= 4). Only one cost-utility analysis 
was provided. In all other cases only budget impact analyses (BIA) was submitted that 
correspond with the national regulatory requirements. Only one analysis included 
hospitalization costs calculation. The chosen perspective was the payer’s perspective 
for all analyses. The time horizon varies between 10 days and 5 years. 68.18% (n= 15) 
of the pharmacoeconomic evaluations were adjusted to 1 year calculations. 72.73% of 
the INNs were approved for 100% reimbursement rate, 3 INNs – for 75% and two-for 
50% reimbursement rate. 45.45% of the submitted evaluations contained local epide-
miological data. Only one analysis did not include the relevant comparator and only 
two haven’t discussed any additional benefits of the treatment. Pharmacoeconomic 
evaluations of new medicinal products was often inadequately validated by incor-
rect type of pharmacoeconomic analysis chosen, lack of Bulgarian epidemiological 
data, costs and effects were not correctly analyzed which led to prolongation of the 
time need for approval. ConClusions: The need for more detailed guidelines is 
obvious in the light of increasing importance of pharmacoeconomic evaluations for 
reimbursement purposes.
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objeCtives: Competitive tendering of active ingredient-specific contracts for 
generic drugs has emerged in Germany due to regulatory changes in 2009. The 
central goal of these changes is to accomplish that small and medium sized firms 
(SME) have better chances to succeed. Another goal is more participation of manu-
facturers, including outright market entry. We study how different designs of the 
competitive tendering affect participation and the outcome of generic drug manu-
facturers. Methods: We use a newly collected data set on almost all of the around 
4000 public competitive awardings of procurement contracts by purchase groups 
in Germany from the first one in 2008 to the end of 2012. An important source of 
cross-sectional variation is caused by the nine purchasing groups, which differ in 
how they design their awarding procedures. Major differences include the lot size, 
the number of possible contracting firms and whether a drugs of a specific active 
pharmaceutical ingredient is auctioned in one or different lots. We use OLS regres-
sions with fixed effects for unobserved active pharmaceutical ingredient (API) mar-
ket characteristics, as well as count data and discrete choice models. Results: Our 
econometric analysis reveals that there are more bidders in tenders where contracts 
with more than one supplier are possible, when the drugs for one API are auctioned 
in a single lot and when the lot size is smaller. Also small firms are more likely to 
win when multiple winners are possible and the lot size is smaller. ConClusions: 
We find that the design of awarding procedures influences participation in tenders 
and, furthermore, the chance of new suppliers to win the contract. This is relevant 
for both purchasing groups and policy makers as low bids and thus drug expenses 
of the statutory health insurances can only be achieved with a competitive industry 
structure.
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